Antiva Biosciences, Inc.

8 articles about Antiva Biosciences, Inc.

• Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO

  4/27/2023

  Antiva Biosciences today announced the closing of a $53 million Series E equity financing.

• Antiva Biosciences Named Winner of Global Women's HealthTech Award By World Bank Group and Consumer Technology Association

  1/6/2022

  Honor Recognizes Companies Advancing Innovative Solutions to Improve Women's Health and Safety in Emerging Markets.

• Antiva Biosciences Closes $31 Million Series D Equity Financing

  11/2/2021

  Antiva Biosciences today announced the closing of a $31 million Series D equity financing.

• 

  Antiva's Gail Maderis Finds Inspiration in Today's Biotech Innovation

  11/9/2018

  Gail Maderis, currently president and chief executive officer of South San Francisco-based Antiva Biosciences, has a rock-solid resume.
• 

  Antiva Biosciences: Case Study in Difficulties Facing Biotechs Focused on Women’s Health

  8/17/2018

  In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.

• Antiva Biosciences Closes $15 Million Series C-1 Financing

  7/10/2018

  Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $15 million in Series C-1 financing led by Hillhouse Capital Management.

• Bay Area's Antiva Grabs $22 Million Series C For HPV Therapy

  3/28/2017

• Chimerix Founder's Antiva Nabs $16 Million and Taps Longtime Biotech Exec as New CEO

  8/6/2015